Serojec
Drugs for Treating Premature Ejaculation
StartupSerojec is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2019. Drugs for Treating Premature Ejaculation. Serojec was founded by Dr. Daniel Drai. The company has 1-10 employees.
The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePre-Funding
- ProductClinical Trial
- ModelB2B
- Employees1-10
- HQTel Aviv-Yafo
- DistrictCenter District
- Last RoundUndisclosed
Dr. Daniel DraiFounder
1 article covered by sources including en.globes.co.il.
What does Serojec do?
Serojec develops drugs to treat premature ejaculation, by combining various drugs on the market. One drug is from the tricyclic family of antidepressants, used in low dosage, which then reaches only the spinal column, not the brain. The second drug is an alkaloid that relaxes the blood vessels. The combination enables each drug to neutralize the other's side effects. The alkaloid is a known drug for the treatment of premature ejaculation. The combinations of both drugs are patented. The company has completed a Phase I trial to verify that the project is safe. A secondary purpose was to show signs of effectiveness. The trial showed that the duration of erection was extended several times over, even though all of the volunteers in the trial were functioning normally. The trial was conducted in cooperation with the University of Vienna.
Who founded Serojec?
Serojec was founded in 2019 by Dr. Daniel Drai (Founder).
What sector is Serojec in?
Serojec operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is Serojec located?
Serojec is based in Tel Aviv, Israel, Center District.